Steven Lichtman
Stock Analyst at Oppenheimer
(2.88)
# 1,569
Out of 5,122 analysts
72
Total ratings
38.46%
Success rate
11.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $18.99 | +15.85% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $251.24 | +45.28% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $75.50 | +65.56% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $70.82 | +44.03% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $88.09 | +53.25% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.78 | +107.61% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $79.06 | +39.13% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $101.84 | -7.70% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $7.94 | +718.64% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $22.15 | -50.33% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $10.49 | +14.39% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $79.37 | +9.61% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.44 | +702.57% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $360.66 | -20.15% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $114.67 | -8.43% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $17.54 | +755.19% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $80.92 | +5.04% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $18.99
Upside: +15.85%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $251.24
Upside: +45.28%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $75.50
Upside: +65.56%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $70.82
Upside: +44.03%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $88.09
Upside: +53.25%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.78
Upside: +107.61%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $79.06
Upside: +39.13%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $101.84
Upside: -7.70%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $7.94
Upside: +718.64%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $22.15
Upside: -50.33%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $10.49
Upside: +14.39%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $79.37
Upside: +9.61%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.44
Upside: +702.57%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $360.66
Upside: -20.15%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $114.67
Upside: -8.43%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $17.54
Upside: +755.19%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $80.92
Upside: +5.04%